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Abstract
Background: One third of infants with congenital hypogonadotropic hypogonadism (CHH) are said to have
micropenis and/or bilateral or unilateral cryptorchidism leading many of them to orchiopexy. Our previous study
in two patients suggests that prolonged subcutaneous infusion of large doses of gonadotropins might normalize
testicular function and growth.
Case presentation: To confirm the effects of early and prolonged subcutaneous infusion of large doses of
gonadotropins on growth and descent of the testes. Eight boys with CHH, aged 0.25–11 months. Testes were
non-palpable in 5 or in high scrotal position in 3. CHH was isolated in 5 infants and part of a syndrome of
combined pituitary hormonal deficits in the 3 others. In response to gonadotropin infusion, mean levels of
testicular hormones were normalized. Complete testis descent occurred in 6 patients. Partial descent occurred in 2.
Testes re-ascended in 1 patient. Testes and penis gained normal dimensions in all cases.
Conclusion: Subcutaneous gonadotropin infusion seems able to induce testis descent in a large proportion of
infants with CHH. If confirmed, this may allow patients to avoid testes surgery but studies in larger series are
needed to evaluate the benefits of this treatment versus traditional orchiopexy.
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Background
Hypogonadotropic hypogonadism (HH) is observed at
birth in infants who have combined pituitary hormone
deficits (CPHD) or isolated hypogonadotropic hypo-
gonadism (IHH), two separate entities that have separate
and multiple genetic etiologies. Cryptorchid or maldes-
cended testes and small testicular volume are clinical
hallmarks of congenital hypogonadotropic hypogonad-
ism (CHH) [1]. We carried out a Pubmed search with
the keywords “cryptorchidism”, “cryptorchid testes”,
“testes descent”, “CHH”, “CPHD”, “hypopituitarism”,
“Kallman”, “isolated HH or idiopathic HH”. Unexpectedly,
this search retrieved only two studies allowing an
estimation of the prevalence of cryptorchidism in patients
with HH. These two studies were carried out in the same
group of patients with IHH [2, 3]. Cryptorchidism was re-
ported in one third of these patients and was bilateral in
half of them or unilateral in the other half [2, 3]. Crypt-
orchidism, particularly if bilateral, is considered to have
additional negative effects on the future fertility of patients
with IHH [2].
A number of studies have examined the effect of
human chorionic gonadotropin (hCG) or recombinant
human LH (rhLH) and FSH (rhFSH) injections upon
testicular descent in common cryptorchidism [4, 5].
Hormonal treatment is associated with testicular descent
in some of these children, but rates generally do not ex-
ceed those seen with placebo by more than 10 % [6].
Surprisingly, a literature search found no comparable
study in infants with CHH, in whom hCG was largely
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used to test testosterone secretion [1], but not for thera-
peutic purposes. In the absence of a systematic study of
hCG treatment upon testes descent in infants with either
IHH or combined pituitary deficits, the data collected in
common cryptorchidism are often used instead, but this
extrapolation may not be justified. We know of only two
studies, totaling 3 infants with CHH, that have used go-
nadotropins in a therapeutic perspective. In the unique
patient treated by Main et al., six months of twice-
weekly subcutaneous injections of rhLH (20 IU) and
rhFSH (21.3 IU) allowed a limited growth of the penis
from 1.6 to 2.4 cm and a 1.7-fold increase of testes vol-
ume [7]. In the two patients treated by Bougnères et al.,
subcutaneous infusion of rhLH and rhFSH at much
higher daily doses of 50 IU and 100 IU were used to
mimic mini-puberty in two infants with CHH [8]. This
treatment induced a tripling of penile length and a 4-
fold increase in testes volume.
The other hormonal treatment that is classically used
in infants with CHH is depot esters of testosterone [9].
Testosterone can be administered im, locally by a testos-
terone lotion or gel, transdermally by a testosterone
patch or suppository. This treatment induces durable
phallic growth but has no effect on testicular volume or
descent. The lack of effect of testosterone alone upon
testis descent contrasts with the classical hypothesis that
the inguinoscrotal phase of testis descent, which takes
place between the 25th and the 35th week of gestation
but often occurs after birth in humans, is androgen-
mediated and is directly affected by the lack of testoster-
one production in fetuses with CHH [10].
The usual treatment of maldescended testes is surgical
orchiopexy. For children with common, so-called
“idiopathic” cryptorchidism, recommendations advocate
orchiopexy at 6–12 months [11]. These recommanda-
tions contrasts with the report collected by Pitteloud
et al. in patients with IHH [3]. This report indicates that
surgical repair was performed in 86 % of patients with
cryptorchidism only between 4 and 35 years of age, at a
mean age of 13 ± 2 years [3]. We have not been able to
find a publication that has specifically examined or
reviewed the indication, prevalence and long term re-
sults of orchiopexy in infants or children with CHH and
cryptorchidism, whether they have IHH, including Kall-
man syndromes, or CPHD. This is even more surprising
considering the fact that the surgical correction of crypt-
orchidism is advocated as a possible means for increas-
ing the likelihood of future fertility [12, 13]. Anecdotical
reports of orchiopexy were found in a number of publi-
cations following a Pubmed search using keywords such
as “orchiopexy”, “CPHD”, “hypopituitarism”, “IHH”,
“Kallmann”. See detailed comments and preferences in
Additional file 1. These publications seems to indicate
that orchiopexy is often used for the treatment of
cryptorchidism in children with various genetic etiolo-
gies of CHH, and that in most cases, orchiopexy is
performed at age 4 years or later, confirming the
observation of Pitteloud et al. [3]. The treatment of
cryptorchidism thus remains a yet-to-be explored
clinical field of research aiming at the preservation of
fertility potential in patients affected with CHH. The
current study focuses on the effects of subcutaneous
continuous recombinant LH and FSH infusion on the
mal-descended testes in neonates with CHH, with the
idea of proposing this treatment as an alternative to
orchiopexy.
Case presentation
Eight patients aged 6.03 ± 3.75 months (0.25–11 months)
had CHH due to CPHD (N = 3) or IHH (N = 5). All in-
fants had normal birth height and weight. All 8 patients
had serum testosterone below 0.3 ng/ml (to convert into
SI units, multiply by 3.47, ie 1 nmol /L) and LH <0.8 U/l
during the time of physiological mini-puberty. The eti-
ology of IHH was KAL1 mutations in two patients,
KAL2 mutations in one patient, SOX2 mutation in one
patient; one patient with IHH remained without
molecular diagnosis. The 3 patients with CPHD had
growth hormone, TSH, ACTH deficiencies and ec-
topic neuro-hypophysis. We have used the classifica-
tion of cryptorchidism proposed by Scorer [14], where
testis location is defined as normal, high scrotal,
supra-scrotal, inguinal or non-palpable [15]. In our
study, 5/8 patients had non-palpable testes and 3/8
had palpable testes in a high non-scrotal position.
Penile length was measured by the method of Schon-
feld [16] the penis is stretched to resistance, and
length is measured along the dorsal aspect from the
pubis to the tip of the glans. Volume of the testes
was carefully determined through palpation and direct
measurement. Clinical characteristics of the patients
are described in Table 1.
Following the favorable preliminary observations
made in 2008 [8], we have since then routinely
applied the subcutaneous infusion of rhLH and rhFSH
to all infants with CHH referred in our department.
The treatment started after explanations were given
to the parents and consent was obtained. Ethical
approval was obtained for the previous study from
our local St Vincent Pediatric Ethical Committee
(SVP-2007-04). rhLH (Luveris 75 IU®) and rhFSH
(Gonal-F 75 IU®) were obtained from Serono (Geneva,
Switzerland) and dissolved in solvent for infusion. A
Paradigm insulin pump (Minimed, Northridge, CA)
whose catheter was changed every 48–72 h was used
for infusion. The biological stability of the infused
rhLH and rhFSH within the pump system was ascer-
tained by the stability of the plasma levels of LH,
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FSH, testosterone and inhibin B (INB) in the first two
infants [8] when sampled at various times such as
12 h and 72 h, the levels of these hormones were
found to be steady. Continuous infusion of rhLH and
rhFSH was administered at a daily rate of 50 and 75–
150 IU, respectively. These doses were used because
we had previously observed that they allowed Leydig
and Sertoli cell hormones to reach the normal range
during minipuberty [17]. Indeed, daily infusion of
50 IU rhLH over 20 weeks induced LH levels of 4.8
± 2.4 IU/ml and testosterone levels at 1.5 ± 0.1 ng/ml
in the two studied infants. For rhFSH infusion rates,
we observed that high daily doses of 75–150 IU
(resulting in FSH levels of 49 ± 17 IU/ml) were
needed to obtain mean values of AMH and inhibin B
(INB) levels of 563 ± 204 pmol/l and 717 ± 234 pg/ml.
In the current report, we have not tested graded infu-
sions nor did we carry out a systematic dose–response
study. Instead we started with daily doses of 50 IU
rhLH and 75 IU of rhFSH, then used an approximate
dose adjustment aiming at maintaining hormone levels
within the normal range of mini-puberty [18, 19]. No
adverse effects were observed at the cutaneous infusion
site in any of the infants.
Classical replacement therapy with growth hormone,
L-thyroxine, and hydrocortisone was administered to the
patients with CPHD.
Serum FSH, LH, AMH, INB and testosterone concen-
trations were measured using RIA in the same labora-
tory as reported [20]. One-sided paired t test was used
to analyze the observed changes of penile length, testis
volume and hormone levels.
Treatment duration was 6 ± 0.58 months. Follow-up
after cessation of gonadotropin infusion was 35.5 months
[13–54 months]. The continuous subcutaneous infusion
of rhLH and rhFSH increased serum gonadotropins and
testosterone, to values normally observed during mini-
puberty (Table 2). However, serum AMH and inhibin B
both failed to reach the normal mini-puberty range in 1/
8 patients.
Mean stretched penile length increased from 20.2 mm
[13–28 mm] to 37.4 mm [30–52 mm] (p < 0.001) in
infants with IHH and from 22.6 mm [18–30 mm] to
44.3 mm [30–70 mm] (p < 0.001) in infants with
CPHD. Mean final testes volume was 1.27 ml [0.61–
2.1 ml] Simultaneously, testicular volume increased
from 0.43 ml [0.1–0.68 ml] to 1.64 ml [0.33–2.1 ml]
(p < 0.001) in the 3 children who had testes palpable
in high scrotal position. The details of testis descent
are shown in Table 2. Among the 5 patients having
their testes in abdominal position, bilateral descent to
the bottom of the scrotum occurred in three (P2, P4
and P6) and bilateral incomplete descent in high
scrotal position occurred in one (P1). One of the 5
patients with abdominal testes (P5) had a descent of
his left testis to the bottom of the scrotum, while his
right testis remained in high scrotal position. In total,
among the 10 testes that were initially located in
abdominal position, complete descent occurred in 7,
and incomplete descent in 3. The three patients who
Table 1 Characteristics of the 8 patients with CHH treated by rhLH and rh FSH infusion
Patients Classification Age at onset
of treatment
(months)














P1 CPHD 6 Non
palpable
18 1 0.61 High scrotal 30 6
P2 CPHD 11 Non
palpable
20 4 2 Intra-scrotal 33 6
P3 CPHD 10 High-
scrotal
30 1 2,1 Intra-scrotal 70 6
P4 IHH 4.5 Non
palpable
21 4 0.76 Intra-scrotal 30 6.5
P5 IHH 2.5 Non
palpable
20 6 0.7 High-scrotal Intra-
scrotal
35 6.5
P6 IHH 9 Non
palpable
19 4 1,16 Intra-scrotal 40 5
P7 IHH 5 High-
scrotal
28 4 0,89 Intra-scrotal 52 5
P8 IHH 0.25 High-
scrotal
13 5 1,95 Intra-scrotal 30 6
IHH isolated hypogonadotropic hypogonadism, CPHD Combined Pituitary Hormonal Deficits (CPHD)
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had testes initially palpable in high scrotal position
showed complete scrotal descent during treatment. In
one case (P4), however, both testes re-ascended
11 months after their descent, thus underwent orchio-
pexy. The cost of rhLH and rhFSH infusions per
studied child over the 6 reported months averages
18,000 USD.
Discussion
A satisfactory sex life and fertility are the two main ob-
jectives of the treatment of CHH. To allow for fertility,
therapeutic regimens proposed in adulthood used the
administration of hCG/HMG or hCG/rhFSH [21–25] or
pulsatile GnRH with or without rhFSH in adolescents
[26, 27]. Cryptorchidism is estimated to affect approxi-
mately one third of patients with IHH [2, 3] and an im-
portant, but unknown proportion of infants with CPHD.
Patients affected with CHH who have cryptorchid tes-
tes have decreased hormonal response to gonadotropins
at adolescence [26] or a less favourable fertility outcome
[2] than those in whom spontaneous testis descent oc-
curred at times of fetal or neonatal life. This may be due
to intrinsic anomalies of the undescended testes, an ac-
quired aggravation of testes abnormalities due to their
prolonged intra-abdominal location [28], or could be
secondary to lesions generated by surgical procedure
needed to move an undescended testis into the scrotum,
which carries a greater risk of damage to the testis when
the testis is very small as in all infants with CHH.
It is noteworthy in this respect that many of the stud-
ies reporting treatment outcomes in male patients with
CHH were biased by the exclusion of patients with
cryptorchidism [22, 24, 29–31]. The good therapeutic re-
sults that have been published regarding gonadotropin
or GnRH treatment of CHH are thus likely to be less fa-
vorable if cryptorchid patients are included, as observed
by Pitteloud et al. [2].
Boys with CHH lack all mini-pubertal hormonal
events [32]. A potential contributor for azoospermia and
infertility in adult men is the deficient proliferation of
immature Sertoli cells in infancy due to FSH insuffi-
ciency. The artificial increase of Sertoli cell activity dur-
ing early infancy might have beneficial effects on
gonadal development, proliferation of immature Sertoli
cells and spermatogonia that will help fertility in adult
life, but this is entirely speculative. The current report
on the effects of rhLH and rhFSH confirms our previous
observation of correction of Sertoli and Leydig hormone
pattern, and growth of phallus length and testes volume
[8]. A new finding was the testicular descent observed in
almost all treated patients. Despite the lack of an un-
treated group and the small number of studied infants,
the current report suggests that early infusion of recom-
binant gonadotropins is able to trigger testes descent in
children with CHH, even when testes are initially in ab-
dominal position. This effect was seen as late as the
17 months of life and therefore does not seem to be
confined to the time of the physiological mini-puberty.
The descent of testes occurred within a mean of four
months following the onset of gonadotropins infusion,
which may be beneficial since a recent study showed a
negative relationship between the duration of a supra-
scrotal position and testicular growth [11]. In a few
cases, the descent induced by gonadotropin infusion
Table 2 Serum concentrations of hormones before and during treatment
Before treatment During treatment
FSH (UI/l) LH (UI/l) Ta (ng/ml) AMH (pmol/l) INB (pg/ml) FSH (UI/l) LH (UI/l) T (ng/ml) AMH (pmol/l) INB (pg/ml)
Patients with CPHD
P1 0.4 0 0.06 103 5 18 1.2 1 264 55
P2 0.03 <0.1 0.02 675 100 21 2.9 1.4 1644 505
P3 0.61 0.7 0.02 1984 155 18 2 2.8 1040 544
Patients with IHH
P4 1 0.4 0.05 125 91 40 4.6 2.8 29 111
P5 0.8 0.1 0.04 595 73 24 4.7 3.3 565 401
P6 0.1 <0.1 0.05 250 5 41 5.4 3.86 666 287
P7 0.3 <0.1 0.02 665 64 32 4.6 3.9 668 514
P8 0.21 <0.1 0.07 270 14 59 9.5 9.6 890 530
Mean value 0.48 0.15 0.04 583 63.3 31b 4.4b 3.6b 721 368
Normal valuesc 0,2–4 0,5–7,1 0.52–4.8 251–679 254–513 0,2–4 0,5–7,1 0.5–4.8 251–679 254–513
IHH isolated gonadotropin deficiency, CPHD Combined Pituitary Hormonal Deficits (CPHD), INB inhibin B
T testosterone
aTo convert T into SI unit (nmol/l), multiply by 3.47
bp < 0.005 vs baseline values
cRange of normal values taken from reference [18, 19]
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may be reversible, since testes re-ascended in one pa-
tient 11 months after their descent. Larger trials will be
necessary to better define the window of efficacy of go-
nadotropin infusion for inducing testis descent.
Our choice of using large doses of rhFSH doses needs
to be discussed. It was dictated by the previous observa-
tion in the first two reported infants [8], in whom we
observed that daily dosages of 50 IU rhFSH per day re-
sulted in circulating levels of AMH and inhibin B well
below the normal range. We then decided to increase
the daily doses to 75–150 IU to force Sertoli cells to pro-
duce AMH and inhibin B at a more physiological level,
as observed in the current report. We speculated that in
patients born with both HH and cryptorchidism, there
may be some resistance of Sertoli cells to FSH, possibly
because of the prolonged lack of exposure to pituitary
FSH during prenatal life.
Another aspect to be discussed in the current report is
the deleterious effect that high circulating gonadotropin
could have on germ cells in cryptorchid testes. Such
deleterious effect have only been reported in boys with
idiopathic cryptorchidism (with or without primary tes-
ticular insufficiency) treated with hCG, not in the CHH
population, or in response to rhLH or rhFSH [33, 34].
Conclusion
The early continuous infusion of rhLH and rhFSH dur-
ing the first months of life seems to allow the descent
and growth of a large proportion of cryptorchid testes in
infants with CHH, as late as the 11th month of life.
These preliminary observations raise several questions.
Which of the two gonadotropins is responsible for the
testis descent? Should this treatment replace the trad-
itional orchiopexy in children with documented CHH?
Would repeated hCG injections allow comparable effects
at a lower cost? hCG is recognized as of limited efficacy
in infants with common cryptorchidism. It is thus pos-
sible, and even likely, that repeated hCG injections
would prove of greater efficacy when cryptorchidism is
related to gonadotrophin deficiency. Owing to its simpli-
city and low cost, this approach, which has not been
studied previously in infants with HH, will need a com-
parative evaluation in the future, both with orchiopexy
and with the rhLH/rhFSH pump approach. Will the fu-
ture fertility benefit from both the early descent of the
testes and the stimulation of Sertoli cell function and/or
proliferation induced by the rhLH and rhFSH infusion?
Only prolonged follow-up of infants and large inter-
national trials will hopefully provide answers to the yet-
to-be solved problem of the early management of
cryptorchidism in CHH. In this regard, a possible merit
of the current report is to bring the case of cryptorchid-
ism associated with CHH in the frontline of future
therapeutic approaches for preserving fertility potential
in these patients.
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